Taken together, these studies in childhood sarcomas, and prostate, and breast cancers suggest that more studies are needed to investigate the potential of components outside the IGF axis to provide valuable predictive biomarkers for IGF-1R inhibition. The gene discussed is IGF1R; the disease is sarcoma.